Regulatory teams dont just interpret the lawthey navigate litigation risk.
Most organizations treat regulatory strategy as a compliance exercise: file the right submissions, meet the right timelines, and keep the regulator satisfied. But in todays ma…
Why Your Regulatory Team Needs to Think Like Drug Patent Litigators Read Post »
Most pharma teams dont fail because they dont understand patents. They fail because they treat patent intelligence like a late-stage insurance policya legal checklist after the science is already locked in.
That late pivot tax is expensive. It shows up…
Bioequivalence is the easy part. Freedom to operate is the cliff.
Everyone in life sciences talks about bioequivalence like its the finish line. Get the PK/PD similarity. Pass the statistical thresholds. Match the same drug, different label promise. Do…
Why Bioequivalence Is the Easy Part and Freedom to Operate Is the Cliff Read Post »
Pharmas safe portfolio story is comfortinguntil you look at the filing math.
For years, many drug companies have pursued a defensible strategy in plain sight: reduce the cost of building patents, file less, and let the strong pieces carry the rest. Its…
The Safe Patent Portfolio Trap: Why Minimal Filing Costs Pharma a Decade of Growth Read Post »
Most Paragraph IV decisions dont fail because the science is wrong. They fail because the filing is sloppy.
In patent litigation, we tend to talk about winning as if its binaryright claim, wrong claim, enough evidence, not enough. But the unglamorous…
The At-Risk Launch Playbook Is Backand Pharma Is Acting Like Math Matters More Than Courts
Heres the hook: In brand drug launches, the story used to be simple: win the case, ship the product, collect the revenue. But the last few years have rewritten t…
The At-Risk Launch: When the Math Says Go, Even If the Court Says No Read Post »
Evergreening is the word everyone loves to hateusually because its used as a blunt weapon in the pricing debate.
But the truth is less satisfying and more actionable: not every patent thicket is a scam, and not every expiration date tells the whole sto…
The Evergreening Myth: How to Spot the Cracks in a 20-Patent Thicket Read Post »
Most people think patent litigation is about winning at the courthouse.
In pharma, thats only half the story. The other half is what happens years earlierwhen teams challenge weak or overly broad methods of use claims before they calcify into an expe…
Sue Early, Win Big: The Hidden ROI of Challenging Weak Method-of-Use Drug Patents Read Post »
The 180-Day Exclusivity Trap: Why First-to-File Winners Still Lose Money
In drug development and generic competition, the phrase first-to-file is often treated like a shortcut to value.
File first under the Hatch-Waxman framework, you win 180 days of e…
The 180-Day Exclusivity Trap: Why First-to-File Winners Still Lose Money Read Post »
Most pharma teams treat patent litigation like a cost center. Thats the mistake.
A settlement can be the right outcomebut it shouldnt be your default playbook.
In todays patent landscape, settle too quickly often turns a litigation strategy into a budg…
Get new actionable insights and updates from BiotechBlog
